Polyhydroxybutyrate-coated magnetic nanoparticles for doxorubicin delivery: Cytotoxic effect against doxorubicin-resistant breast cancer cell line

American Journal of Therapeutics

Volumn 21, Issue 6, 2014, Pages 453-461

  Yalcin, Serap ^a   Unsoy, Gozde ^b   Mutlu, Pelin ^b   Khodadust, Rouhollah ^b   Gunduz, Ufuk ^b  

^a AHI EVRAN UNIVERSITY   (Turkey)

^b MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Doxorubicin; Drug resistance; Magnetic nanoparticles; PHB; Targeted drug delivery

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; HYDROXYBUTYRIC ACID; MAGNETITE NANOPARTICLE;

BREAST NEOPLASMS; CHEMISTRY; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG RESISTANCE; DRUG STABILITY; DRUG STORAGE; FEMALE; HUMAN; MCF 7 CELL LINE; PATHOLOGY; PH; TIME; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; DRUG STORAGE; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXYBUTYRATES; MAGNETITE NANOPARTICLES; MCF-7 CELLS; TIME FACTORS;

EID: 84914151125     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000066     Document Type: Article

References (47)

1. Gelperina S, Kisich K, Iseman MD, et al. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172:1487-1490.
2. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3:133-149.
3. Provenzale JM, Silva GA. Uses of nanoparticles for central nervous system imaging and therapy. AJNR Am J Neuroradiol. 2009;30:1293-1301.
4. Matsunaga T, Sato R, Kamiya S, et al. Chemiluminescence enzyme immunoassay using protein A-bacterial magnetite complex. J Magn Magn Mater. 1999;194:126-131.
5. Bazylinski DA. Controlled biomineralization of magnetic minerals by magnetotactic bacteria. Chem Geology. 1996;132:191-198.
6. Taylor JI, Hurst CD, Davies MJ, et al. Application of magnetite and silica-magnetite composites to the isolation of genomic DNA. J Chromatogr A. 2000;890:159-166.
7. Mornet S, Vekris A, Bonnet J, et al. DNA-magnetite nanocomposite materials. Mater Lett. 2000;42:183-188.
8. Reetz MT, Zonta A, Vijayakrishnan V, et al. Entrapment of lipases in hydrophobic magnetite-containing sol-gel materials: magnetic separation of heterogeneous biocata-lysts. J Mol Catal A: Chem. 1998;134:251-258.
9. Yigit MV, Moore A, Medarova Z. Magnetic nanoparticles for cancer diagnosis and therapy. Pharm Res. 2012;29: 1180-1188.
10. Miller E, Peppas NA, Winslow DN. Morphological changes of ethylene/vinyl acetate based on controlled delivery systems during release of water-soluble solutes. J Memb Sci. 1983;14:79-92.
11. Zhao X, Harris JM. Novel degradable poly(ethylene glycol) hydrogels for controlled release of protein. J Pharm Sci. 1998;87:1450-1458.
12. Ruiz JM, Benoit JP. In vivo peptide release from poly (lactic-coglycolic acid) copolymer 50/50 microspheres. J Cont Rel. 1991;16:177-186.
13. Li JK, Wang N, Wu XE. A novel biodegradable system based on gelatin nanoparticles and poly(lactic-co-glycolic acid) microspheres for protein and peptide drug delivery. J Pharm Sci. 1997;86:891-895.
14. Akiyoshi K, Sunmoto J. Supramolecular assembly of hy-drophobized polysaccharides. Supramol Sci. 1996;3:157-163.
15. Jeong Y, Nah J-W, Na K, et al. Self assembling nano-spheres of hydrophobized pullulans in water. Drug Dev Ind Pharm. 1999;25:917-927.
16. Schwick HG, Heide K. Immunochemistry and immunology of collagen and gelatin. Bibl Haematol. 1969;3: 111-125.
17. Massia SP, Stark J, Letbetter DS. Surface immobilized dextran limits cell adhesion and spreading. Biomaterials. 2000;21:2253-2261.
18. Maia JL, Santana MHA, Re MI. The effect of some processing conditions on the characteristics of biodegradable microspheres obtained by an emulsion solvent evaporation process. Braz J Chem Eng. 2004;21:1-12.
19. Lee SY. Bacterial polyhydroxyalkanoates. Biotechnol Bioeng. 1996;49:1-14.
20. Madison LL, Huisman GW. Metabolic engineering of poly(3-hydroxyalkanoates): from DNA to plastic. Micro-biol Mol Biol Rev. 1999;63:21-53.
21. Kim GJ, Bang KH, Kim YB, et al. Preparation and characterization of native poly(3-hydroxybutyrate) micro-spheres from Ralstonia eutropha. Biotechnol Lett. 2000; 22:1487-1492.
22. Pouton CW, Akhtar S. Biosynthetic polyhydroxyalka-noates and their potential in drug delivery. Adv Drug Deliver Rev. 1996;18:133-162.
23. Kars MD, Iseri OD, Gunduz U, et al. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res. 2006;26:4559-4568.
24. Xiong YC, Yao YC, Zhan XY, et al. Application of poly-hydroxyalkanoates nanoparticles as intracellular sustained drug-release vectors. J Biomater Sci Polym Ed. 2010;21:127-140.
25. Gittleman JI, Abeles B, Bozowski S. Superparamagnet-ism and relaxation effects in granular Ni-SiO2 and Ni-Al2O3 films. Phys Rev B. 1974;9:3891-3897.
26. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by Numbers. Lancet Oncol. 2005;16:112.
27. Neuberger T, Schopf B, Hofmann H, et al. Superpara-magnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater. 2005;293:483.
28. Erdal E, Kavaz D, Sam M, et al. Preparation and characterization of magnetically responsive bacterial polyester based nanospheres for cancer therapy. J Biomed Nanotech-nol. 2012;8:1-9.
29. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165-1170.
30. Ankamwar B. Biosynthesis of gold nanoparticles (Greengold) using Leaf Extract of Terminalia catappa. E-J Chem. 2010;7:1334-1339.
31. Unsoy G, Yalcin S, Khodadust R, et al. Synthesis optimization and characterization of chitosan-coated iron oxide nanoparticles produced for biomedical applications. J Nanopart Res. 2012;14:964-977.
32. Hong K, Sun S, Tian W, et al. A rapid method for detecting bacterial polyhdroxyalkanoates in intact cells by Fourier transform infrared spectroscopy. Appl Microbiol Biot. 1999;51:523-526.
33. Schmid R. Recent advances in the description of the structure of water, the hydrophobic effect, and the like-dissolves-like rule. Monatshefte für Chem. 2001;132:1295-1326.
34. Khodadust R, Mutlu P, Yalcin S, et al. Doxorubicin loading, release and stability of polyamidoamine dendrimer-coated magnetic nanoparticles. J Pharm Sci. 2013;102: 1825-1835.
35. Min KH, Park K, Kim YS, et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated campto-thecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release. 2008;127:208-218.
36. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21:5-13.
37. Kassab AC, Xu K, Denkbas EB, et al. Rifampicin carrying polyhydroxybutryrate microspheres as a potential che-moembolization agent. J Biomater Sci Polym Ed. 1997;8: 947-961.
38. Wang HT, Palmer H, Linhadrt RJ, et al. Degradation of poly (ester) microspheres. Biomaterials. 1990;11:679-685.
39. Gaucher G, Poreba M, Ravenelle FO, et al. Poly (N-Vinyl-Pyrrolidone)-Block-Poly(D, L-Lactide) as polymeric Emulsifier for the preparation of biodegradable nanopar-ticles. J Pharm Sci. 2007;96:1763-1775.
40. Gogolewski S, Jovanovic M, Perren SM, et al. Tissue response and in vivo degradation of selected polyhydrox-yacids: polylactides (PLA), poly (3-hydroxybutyrate) (PHB), and poly (3-hydroxybuyyrate-co-3-hydroxyvaler-ate) (PHB/VA). J Biomed Mater Res. 1993;27:1135-1148.
41. Sharma R, Awasthi YC, Yang Y, et al. Energy dependent transport of xenobiotics and its relevance to multidrug resistance. Curr Cancer Drug Targets. 2003;3:89-107.
42. Carvalho FS, Burgeiro A, Garcia R, et al. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014;34:106-135.
43. Sugiyama S, Yamada K, Hayakawa M, et al. Approaches that mitigate doxorubicin-induced delayed adverse effects on mitochondrial function in rat hearts; liposome encapsulated doxorubicin or combination therapy with antioxidant. Biochem Mol Biol Int. 1995;36:1001-1007.
44. Villani F, Galimberti M, Monti E, et al. Effect of flunar-izine on the delayed cardiotoxicity of doxorubicin in rats. Pharmacol Res. 1991;23:195-202.
45. Perletti G, Monti E, Paracchini L, et al. Effect of trimeta-zidine on early and delayed doxorubicin myocardial tox-icity. Arch Int Pharmacodyn Ther. 1989;302:280-289.
46. Lum BL, Svec JM, Torti FM. Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity. Drug Intell Clin Pharm. 1985;19:259-264.
47. Kalaria DR, Sharma G, Beniwal V, et al. Design of biodegradable nanoparticles for oral delivery of doxorubi-cin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2009;26:492-501.